The 5-Second Trick For Z-LEHD-fmk
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo targets were being To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis pe